Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Express Scripts
Citi
Daiichi Sankyo
Farmers Insurance
Julphar
Argus Health
Dow
Cipla

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

« Back to Dashboard

Clinical Trials for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate

Trial ID Title Status Sponsor Phase Summary
NCT00004284 Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 3 OBJECTIVES: I. Evaluate the ability of a slow-releasing formulation of neutral potassium phosphate to correct hypercalciuria and prevent recurrent stone formation in patients with absorptive hypercalciuria. II. Evaluate the safety of this treatment. III. Compare the efficacy of potassium phosphate to that of potassium citrate.
NCT00004284 Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria Completed University of Texas Phase 3 OBJECTIVES: I. Evaluate the ability of a slow-releasing formulation of neutral potassium phosphate to correct hypercalciuria and prevent recurrent stone formation in patients with absorptive hypercalciuria. II. Evaluate the safety of this treatment. III. Compare the efficacy of potassium phosphate to that of potassium citrate.
NCT00004284 Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria Completed National Center for Research Resources (NCRR) Phase 3 OBJECTIVES: I. Evaluate the ability of a slow-releasing formulation of neutral potassium phosphate to correct hypercalciuria and prevent recurrent stone formation in patients with absorptive hypercalciuria. II. Evaluate the safety of this treatment. III. Compare the efficacy of potassium phosphate to that of potassium citrate.
NCT00120731 Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones Completed Children's Mercy Hospital Kansas City N/A High amounts of calcium in the urine (hypercalciuria) can cause development of kidney stones in children. Treatment for these children includes plenty of fluids, a low-salt diet and medications such as potassium citrate. A major advantage of potassium citrate, as compared to hydrochlorothiazide, is its lack of side effects. One problem the researchers and others have observed is that some children continue to form kidney stones despite correction of hypercalciuria with potassium citrate. One possible explanation is that in some individuals potassium citrate therapy results in an excessive elevation of urine pH, a situation that may predispose to calcium phosphate stone formation. In this study, the researchers will study the effects of potassium citrate on urine chemistries and acid-base balance in three groups of children aged 5-17 years: - children who are hypercalciuric stone formers; - healthy children without a history of hypercalciuria or kidney stones. Particular attention will be paid to try to identify those who develop a very high urine pH (>8) and the factors leading to this metabolic reaction. The researchers will try to learn whether it is the child’s characteristics, the disease manifestations, the dose of the drug, or a combination of the above which may be the cause of the development of very alkaline urine. Based on the results, the researchers hope to be able to better “tailor” the individual treatment for each child with kidney stones.
NCT00291720 Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure? Completed British Heart Foundation Phase 2 Patients with kidney failure have a poor survival rate that is due to a much higher than average rate of heart and vascular disease. The reason that kidney failure causes heart disease is unknown but recent research suggests that a hormone called aldosterone, which is increased in patients with kidney disease may damage the heart and blood vessels. The investigators propose, using a randomized blinded trial, to find out whether drugs that inhibit the actions of aldosterone have beneficial effects on the cardiovascular system in patients with kidney failure
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate

Condition Name

Condition Name for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate
Intervention Trials
Hypercalciuria 2
Healthy 2
Colon Cancer 2
Kidney Calculi 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate
Intervention Trials
Nephrolithiasis 4
Kidney Calculi 4
Hypercalciuria 3
Calculi 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate

Trials by Country

Trials by Country for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate
Location Trials
United States 11
Canada 3
India 3
Switzerland 2
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate
Location Trials
Minnesota 2
California 2
Missouri 1
New York 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate

Clinical Trial Phase

Clinical Trial Phase for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate
Clinical Trial Phase Trials
Phase 4 7
Phase 3 3
Phase 2/Phase 3 2
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate
Clinical Trial Phase Trials
Completed 12
Recruiting 7
Active, not recruiting 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate

Sponsor Name

Sponsor Name for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate
Sponsor Trials
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2
National Institutes of Health (NIH) 2
University of California, San Francisco 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dextrose; Magnesium Chloride; Potassium Chloride; Potassium Phosphate, Dibasic; Sodium Acetate
Sponsor Trials
Other 38
NIH 7
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Moodys
Federal Trade Commission
McKinsey
Chinese Patent Office
Deloitte
Healthtrust
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.